Background and Aim: Recent observational studies document that non-adherence to mesalamine therapy during remission is frequent. We aimed to investigate patient impact of patient education using objective assessments of adherence. No difference between the intervention group and standard care was seen in IBDQ, partial adherence, self-assessment of adherence, or therapy satisfaction at all visits. We suggest a model in which individual risks for non-adherence are driven by patients with young age, short disease duration, and low education levels. Conclusions: Non-adherence is frequent in a population with quiescent/mildly active UC. Although more than 25% of the population was not in remission at the various time points, no relationship between disease activity and adherence was seen over the 14-month observation period. Physicians should maximise their efforts to motivate high-risk patients for adherence. Future trials should use objective exposure assessments to examine the impact of continuous education and consultations on the background of individual risks to develop non-adherence.
Background
Ulcerative colitis [UC] is a chronic inflammatory bowel disease with significant negative impact on quality of life and psychological, physical, and social well-being. Typically, acute phases alternate with phases of remission, in which anti-inflammatory therapies used to control disease activity can be reduced. 1, 2, 3 However, 30-50% of patients develop a chronic active disease. 1 The aetiology of the disease is unknown, but relates to a polygenic susceptibility affecting innate and adaptive immune regulation and epithelial cell health, among other factors. 4 Chronic pharmacotherapy of UC targets both asymptomatic as well as symptomatic phases. It focuses on induction of remission by reducing signs and symptoms of disease and promoting mucosal healing. Maintenance therapy is used to prolong remission periods; 5-aminosalicylates [5-ASA, such as mesalamine] represent the most widely used class of drugs for induction and maintenance of remission in mild to moderate ulcerative colitis. Many patients can be maintained on mesalamine monotherapy. Besides its anti-inflammatory mechanism, retrospective correlative studies have suggested that the long-term use of mesalamine in IBD patients may significantly reduce the risk of development of UC-associated colorectal cancer and may prevent sporadic colorectal carcinoma, too. 5, 6 The optimisation of this maintenance strategy would be therefore beneficial to the overall long-term outcome of disease.
Non-adherence to chronic medication in IBD is high, with 43% to 60% of patients showing non-adherence. 7, 8, 9 In addition to the direct medication-related costs, non-adherence to mesalamine therapy during remission appears to be an important factor that is associated with relapse in UC. 8, 10, 11 The reasons for non-adherence are largely unknown. The load of tablets and the daily frequency of administration may be parameters that influence adherence. 12 A lack of understanding of the benefits of a chronic medication may contribute to non-adherence behaviour. 13 Patient education can dramatically improve patient knowledge. 14 Recall of medical information that is administered through education was a significant predictor for self-reported medication intake behaviour. 15 The use of a web-based concept for patient education was accompanied by a higher intake rate for mesalamine during acute disease. 16, 17 Patient education may therefore improve adherence. However, access to telemedicine did not improve patients' quality of life or self-reported adherence. 18 Nevertheless, self-reported adherence may not reflect true intake of drugs. We investigated the influence of a structured patient education intervention on mesalamine adherence using an objective readout [ie urine excretion of 5-ASA and metabolites] in a 14-`1month randomised, prospective clinical trial. A secondary aim was the investigation of sociodemographic and clinical parameters associated with non-adherence.
Patients and Methods

Study design
We report the results of a multi-centre, open, randomised, interventional, two-armed, controlled, non-blinded trial. The trial has been registered under the German Clinical Trials Register [drks] [www. drks.de] under the acronym 'AdCo' [Adherence Colitis], Clinical Trial number: DRKS00008905; 259 patients were eligible for inclusion. One patient withdrew consent before randomisation; 248 patients were randomised to either receive standard care alone or to receive an additional standardizsd education intervention. For the exact study flow plan, see Figure 1 .
Inclusion criteria
Minimum age was 18 years and the diagnosis of ulcerative colitis had to be confirmed by colonoscopy and histology, with a minimum duration of disease of 2 years. Individual exceptions by the lead principal investigator could be given to included patients at and above 16 years. At inclusion, disease activity had to reflect remission or mild disease (colitis activity index [CAI] ≤ 9) 19 and the patient had to be on a treatment with mesalamine [irrespectively of any other treatment] or had to be willing to start a treatment with oral mesalamine with a dose of 1.2 to 4.8 g/day [d] upon inclusion. Rectal formulations of mesalamine alone did not qualify for inclusion. Mesalamines prescribed in the study by the outpatient physician comprised the Claversal ® , Mezavant ® , Pentasa ® , and Salofalk ® formulations. It was not requested to prescribe a particular formulation. All patients included in this study were insured in the German health care system. Therefore medication was provided to all patients by the insurance system, without patients having to pay for it. All patients had to give written informed consent and had to be willing and able to follow a standardised education programme.
Exclusion criteria
Patients with Crohn's disease or indeterminate colitis were excluded, as well as patients with significant comorbidities. Patients with a CAI > 9 were excluded as well as patients with intolerance/contraindication to mesalamine. Also patients after colectomy, as well as patients with a current ostomy, could not participate in the trial.
Concomitant medication
All concomitant medication was allowed, with no restrictions to the dose.
Endpoints
Primary endpoint
Primary endpoint was durable adherence to mesalamine treatment, compared between patients undergoing education and the standard care group (intention-to-treat [ITT] population). Adherence was assessed by Morisky Medication Adherence Scale [MMAS] 19 at each visit. It should be pointed out that the MMAS has been previously validated in other chronic diseases, including arterial hypertension, 20 but not IBD; 0-1 points on the MMAS scale are considered as low adherence, 2-3 points as medium adherence, and 4 points [maximum] as highly adherent. The adherence rating was corrected [decreased] in case of missing confirmation of drug exposure in urine samples. Missing or delayed [more than 4 weeks] visits were rated as low adherence.
A patient was considered adherent [primary endpoint] if all visits in the follow-up phase were at medium or high adherence or if at most one visit was rated as low adherence. Patients with two or more low adherence visits were considered non-adherent.
Secondary endpoints
Secondary endpoints included short-term adherence, quality of life, disease activity, and self-assessment of adherence. Secondary endpoints were evaluated in the ITT population. Self-assessment of adherence was measured by the MMAS 21 as described above. To evaluate short term adherence, adherence data at the end of the supervision phase were used. Data of the MMAS-scale were correlated with results of the 5-ASA-measurements in the urine and corrected, if applicable. analysis. An optimal cut-point on the probability scale of the prediction model was determined by assessing sensitivity and specificity. A nomogram was calculated using rms package in R [version 3.1.0 2014]. 23 Mesalamine, its metabolite, and quality of life [QoL as IBDQ-D sum] were evaluated over time. Data for patients whose measurements were below the lower limit of quantification were imputed by 1.25 and 2.5 for mesalamine and its metabolite, respectively. We applied generalised linear mixed models [GLMM] to cope with nonnormality of the outcomes and the repeated measures during the study. For all outcomes and analysed influencing factors, the same model was fitted: outcome = visit factor [visit*factor]. The statistical 
Study procedures
2.9.1. Education programme sPatients randomised to the education group received a standardized education programme delivered by either a certified nurse or the trial physician, who used a standardised slide set and underwent training beforehand. This was followed by a group session in which all participants asked questions. A contact for further individual questions [eg by telephone or email] was established, which was used in up to 70% of the patients in both groups without difference. A mandatory training programme ensured standardised delivery of the programme. The education programme, which was administered within 4 weeks after inclusion, comprised slide presentation of at least 2 h and consecutive discussion. The presentation comprised modules summarising aetiology of UC, course of disease, complications, therapy regimen [including the necessity and benefits of mesalamine therapy], and strategies to prevent acute relapses. Patients randomised to the control group were offered participation in the education programme also after termination of the study. The German education slide set is attached as a supplement, available at ECCO-JCC online.
Measurement of 5-ASA [urine analysis]
Measurements of 5-ASA and the metabolite N-acetyl-5-ASA were determined by high-performance liquid chromatography [HPLC] , similarly to a previously described method. 25 Urine samples were thawed on the day of analysis. HPLC analysis was performed on an Agilent 1200 system equipped with quaternary pump G1311A, degasser G1322A, autosampler G1329A, and fluorescence detector G1321A. The injection volume was 5 µl. HPLC separation was performed on a Zorbax Eclipse XDB-C18 column [150 × 4.6 mm I.D., 5- Gradient runs started with 0% B and a flow rate of 0.8 ml/min until 3 min, then linear increase to 1.2 ml/min to 3.5 min, remaining at 0% B and 1.2 ml/min to 8 min, then increase to 25% B to 10 min, remaining at 25% B and 1.2 ml/min to 13 min, then re-equilibration to 0% B and a flow rate of 0.8 ml/min. Calibration samples were prepared by adding varying amounts of 5-ASA and N-acetyl-5-ASA to blank urine [3. 125 µg/ml to 200 µg/ml for 5-ASA and 6.25 µg/ml to 400 µg/ml for N-acetyl-5-ASA].
2.10. Visit schedule 2.10.1. Screening phase A baseline physical examination was conducted and patient demographics were recorded. Patients were also asked to fill in a questionnaire regarding their education level, date of diagnosis, operations, current complaints regarding their disease, and medication intake habits. At day 0 [d0, visit 1] patients were randomised to either the standard care or the education group. 
Supervision-phase
Education visit
Education was administered during a dedicated study visit between d0 and Week 4.
No knowledge test about the disease and its therapy was taken at study entry because of a concern that this could have already an educational input influencing adherence. 
Patient disposition and study flow
In all, 259 patients with inactive or mildly active UC were assessed for eligibility. Of the 258 randomised patients, 248 were included in the ITT collective; 11 patients were excluded from the ITT collective in accordance with the study protocol. There was no particular exclusion of patients receiving biologics. Detailed reasons for withdrawal are given in the CONSORT statement [ Figure 1 
Results
Patient groups were well balanced with regards to disease activity, disease localisation, and clinical and sociodemographic characteristics. Concomitant therapies were similar in both groups, with the exception of current anti-tumour necrosis factor 
Primary endpoint
The primary endpoint of improved durable adherence to mesalamine treatment throughout the study through an education programme was not met. 
Secondary endpoints
All secondary endpoints were not different between the intervention group and standard care. Neither the IBDQ, short-term adherence, nor self-assessment of either adherence or therapy satisfaction at all visits showed any significant differences between groups.
Subgroup analyses-anti-TNF
Since anti-TNF medication was the only baseline variable that was different between the two study arms, we repeated the primary analysis under consideration of anti-TNF medication. The stratified analysis, using the Cochrane-Mantel-Haenszel test, shows under adjustment for anti-TNF medication that the study arms cannot be considered different with respect to their adherence rates [ITT collective, p = 0. 
Sociodemographic and disease characteristics and adherence
A planned analysis of the influence of sociodemographic and disease characteristics was conducted for the primary endpoint [ Figure 2 
Identifying factors influencing adherence
In the multivariable model, ie adjusting for confounding factors, we could show that older patients have a higher probability of being adherent; females are more likely to be adherent by factor 3. Patients who judge themselves as adherent on the MMAS scale are very likely adherent. Also patients with higher scores on the IBDQ emotional subscale have a higher chance of being adherent. Interestingly, patients with less clinical activity as evidenced by lower disease activity scores and higher IBDQ values are more likely to be adherent. Therefore disease activity could be an important driver for adherence.
Modelling adherence
We used the multivariate regression analysis to develop a hypothetical score that related to adherence in our study [see Table 2 , Figure 3A and B]. The receiver operator curve in Figure 3C demonstrates a satisfactory predictive power [AUC = 0.822, 95% CI: 0.765-0.877]. A cut-off value of 0.5 [on the probability scale] shows a modest specificity [48%] and a considerable sensitivity [80%] to predict adherence. The score calculated in this model putatively described the individual risk for each patient to develop non-adherence, but needs to be confirmed by a replication experiment.
Urine levels of 5-ASA and its metabolite, sociodemographic factors, and disease characteristics
In a post-hoc analysis we related adherence to sociodemographic and disease characteristics [Figures S1-S2, available at ECCO-JCC online]. Figure S1 demonstrates the relationship with age, which was already detected using aggregated data. This association is seen in the analysis of 5-ASA metabolites, too [ Figure S2 ].
Internal validation of the score
We used a cross-validation approach to assess the model properties. 
Discussion
Non-adherence to prescribed medications is a common problem and can be observed in many chronic diseases. 26, 27 It is one of the most serious problems with regard to direct costs by lost medications and by increasing general health care costs as a result of poor health outcomes, disease-related complications, lost productivity, and compromised quality of life. 28 It has been previously shown that greater belief in treatment necessity positively influences adherence in chronic immune-mediated inflammatory diseases. 29 It can be assumed that the education intervention has improved patient knowledge and insight about the necessity of medical treatment. Written information when reinforced verbally, as it was administered here, is most effective in improving patient knowledge. 30 The education tool used in the trial had been previously developed and optimised by the German Competence Network for IBD in a patient and physician-assisted version. In previous studies, such interventions led to increased patient knowledge and satisfaction. 28, 31 In most studies, selfreported adherence was assessed in a non-controlled design and it was not verified through objective assessments [ie drug exposure testing].
In our study, we could not show a difference in adherence between patients receiving patient education and the control group. All secondary endpoints that allowed for a less stringent definition of adherence also failed to show a difference. The use of urine levels of 5-ASA provides an objective assessment for adherence. The use of this more objective measure could have contributed to the negative outcome of the study which contrasts other studies showing that patient education had a positive effect on self-reported adherence. In addition, it is impressive to see high non-adherence rates in a situation in which patients know that objective parameters of drug exposure are analysed on an individual level. The high level of non-adherence seen in the study clearly underscores need for measures to improve patient adherence. The under-use of mesalamine may be driving factor of relapse, which is associated with large health care costs. 32 Frequent relapses eventually will promote development of a problematic long-term course of disease 33, 34 with chronic anatomical destruction due to non-controlled inflammation. Whereas mesalamine is a good indicator for overall adherence it is most likely that non-adherence is a problem that is seen across all medications. Medication use statistics [ie prescription renewal] indicate that use of these drugs also suffers from a significant non-adherence rate. 35 With the trend to more effective [and more expensive] oral and subcutaneous therapies for IBD, non-adherence is a large problem that conflicts with the desired positive impact on outcome in IBD. Adherence to therapy with mesalamine was used as a marker in our study to characterise patient behaviour. Theoretically, patients may not have taken their mesalamine because they were not convinced about its [low level] of efficacy in comparison with other, more powerful options. We think this is unlikely, because no difference in adherence was seen between patients who had been advanced to anti-TNF therapy and those receiving oral drugs only.
It is likely that non-adherence is a problem for self-administered study drugs in clinical trials, too, and may therefore affect the differentiation between active drug and placebo when new medications are developed.
Absolute rates of non-adherence were high in our patient population. It is possible that the selection of patients [ie many patients already receiving stepped-up care beyond 5-ASA] has contributed to this. The drugs given in addition to mesalamine [ie further tablets and/or injections/infusions] add to the burden of medication, which could decrease adherence in general. In most cases, there were additional elements of active therapy prescribed for the remaining disease symptoms. However, it is unlikely that patients did specifically decide against taking their mesalamine because aminosalicylates were not just given as a baseline medication for inflammation but also to protect against cancer. Conversely, one could discuss whether a more 'simple' patient population [ie from primary care centres] could not have shown even higher non-adherence rates, because the disease burden and hence the motivation in such a population could be smaller. Future studies should therefore stratify patients by therapeutic intensity and create large enough subgroups including disease burden. Non-adherence is a multi-layer problem and therefore needs to be combated using every possible intervention. Educational interventions alone seem to be not sufficient. Several trials have shown that instruction of patients in self-management strategies is able to increase adherence 36 as well as constant checks of the current therapy and efforts to simplify dosage. 37, 38 Although we hoped that a one-time patient education programme would promote adherence throughout the entire observation period, one could argue that an ongoing or a shorter intervention would lead to a more sustained impact. To optimise knowledge transfer, in future trials patient education should be tested. The assessment of 5-ASA and its metabolites is a strong tool to detect even temporary changes in adherence. It is disappointing to not even see a trace of the intervention within the first few weeks of results. Therefore combined interventions may be more effective. Ideally, one should examine a continuous, intensified subgroup analyses intervention strategy, with patient education that after administration in a group is repeated individually, employs internet resources, and feeds personal exposure/adherence data back to the patients. This is a remarkable observation, because it would be anticipated that at higher need for therapy and a higher burden of acute disease should lead to higher adherence rate. In future studies of patient adherence, it should be examined whether this observation is reproducible and whether it is specific to patients with an inflammatory bowel disease. It could be that patients with IBD initially neglect their disease, and therefore short disease duration is associated with an unwillingness to commit to [lifelong] chronic medication. Further to this, high clinical activity [which is demonstrated by low IBDQ values] could be accompanied by general problems of the digestive tract [eg nausea]. This could be another factor leading to non-adherence to oral medication. In earlier studies adherence was very low, too, and self-reported adherence was affected by multiple daily dosings and full-time employment. 39 We have generated a post-hoc model that marks a patient population that should receive particular attention in both clinical practice and clinical trials. Our hypothetical score in this model, which needs to be prospectively evaluated, could help to better define such problem patients and recruit them to intervention studies. It is therefore important to replicate our findings and to derive a practical definition of the patient population at particular risk for non-adherence. If replicated, it 2  20  25  30  35  40  45  50  55  60  65  70  75  80   65  60  55  50  45  40  35  30  25  20   10  9  8  7  6  5  4  3 
